Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM · NASDAQ Global Select
-$0.39 today
Vol 0.31M · Avg 0.26M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CTNM · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$58.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.95, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 -100.0% | $50.0M | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $258.0K | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 +100.0% | -$258.0K -100.5% | $50.0M | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | 100.0% | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $51.5M +35.0% | $38.2M +38.3% | $27.6M +63.4% | $16.9M -24.4% | $22.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $16.5M +32.6% | $12.5M +97.3% | $6.3M +8.5% | $5.8M -7.3% | $6.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $68.1M +34.4% | $50.6M -23.4% | $66.1M +190.8% | $22.7M -20.7% | $28.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $323.0K +25.2% | $258.0K +32.3% | $195.0K -40.7% | $329.0K +1.2% | $325.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$59.7M -42.0% | -$42.0M -278.2% | $23.6M +200.2% | -$23.5M +16.9% | -$28.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | 47.1% | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$68.1M -33.7% | -$50.9M -216.6% | -$16.1M +29.2% | -$22.7M +20.7% | -$28.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | -32.2% | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $8.2M -7.4% | $8.9M +93.3% | $4.6M +505.3% | $761.0K +888.3% | $77.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $208.0K -46.4% | $388.0K +16.9% | $332.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $8.1M -6.4% | $8.6M -78.0% | $39.2M +2660.1% | -$1.5M -333.1% | -$354.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$60.0M -41.9% | -$42.3M -282.4% | $23.2M +195.5% | -$24.3M +16.4% | -$29.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | 46.3% | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 -100.0% | $450.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$60.0M -41.9% | -$42.3M -286.0% | $22.7M +193.7% | -$24.3M +16.4% | -$29.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | 45.4% | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -33.1% | -$2 -1353.8% | $0 +113.4% | -$1 +15.7% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -33.1% | -$2 -1353.8% | $0 +113.4% | -$1 +15.7% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $27.7M +7.1% | $25.9M +2.9% | $25.1M +0.0% | $25.1M +0.0% | $25.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $27.7M +7.1% | $25.9M +2.9% | $25.1M +0.0% | $25.1M +0.0% | $25.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Alto Neuroscience, Inc.
NYSE:ANRO
$779.61M
Candel Therapeutics, Inc.
NASDAQ:CADL
$438.11M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$389.07M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$350.33M
Amarin Corporation plc
NASDAQ:AMRN
$334.44M
Silence Therapeutics plc
NASDAQ:SLN
$324.73M
AC Immune S.A.
NASDAQ:ACIU
$240.19M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$116.42M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.79M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CTNM generate?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported $0.00 of revenue in fiscal 2025.
Is CTNM profitable?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported -$59,978,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.